Details of the Drug Combinations

General Information of This Drug (ID: DMGLP6S)

• Drug Name: Sarpogrelate (DMGLP6S)
• Synonyms: Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid

Indication

Diabetic complication; ICD 11: 5A2Y; Status: Approved [1]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

25 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dihydroergotamine + Sarpogrelate	DC4HI4C	Dihydroergotamine	DD2 (Cell Line: DD2)	[2]
Dihydroergotamine + Sarpogrelate	DC1LIKE	Dihydroergotamine	Hepatoblastoma (Cell Line: HB3)	[2]
Doxepin + Sarpogrelate	DCWX6XW	Doxepin	DD2 (Cell Line: DD2)	[2]
MK-4815 + Sarpogrelate	DCO8QME	MK-4815	DD2 (Cell Line: DD2)	[2]
MK-4815 + Sarpogrelate	DCUMQL3	MK-4815	Hepatoblastoma (Cell Line: HB3)	[3]
Omacetaxine mepesuccinate + Sarpogrelate	DCIFID4	Omacetaxine mepesuccinate	DD2 (Cell Line: DD2)	[2]
Omacetaxine mepesuccinate + Sarpogrelate	DCUAPX1	Omacetaxine mepesuccinate	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Lumefantrine	DCMPY33	Lumefantrine	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + Dihydroergotamine	DCL078C	Dihydroergotamine	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + Thiolactomycin	DCO72CW	Thiolactomycin	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + MK-4815	DC6CWYI	MK-4815	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + Mefloquine	DCM3YVP	Mefloquine	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + Atovaquone	DCL7PCN	Atovaquone	DD2 (Cell Line: DD2)	[2]
Sarpogrelate + Lumefantrine	DCWQ7O7	Lumefantrine	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Dihydroergotamine	DCDRZWM	Dihydroergotamine	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Epothilone B	DC9YWTO	Epothilone B	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Miconazole	DCLPUFC	Miconazole	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Omacetaxine mepesuccinate	DCYSPVE	Omacetaxine mepesuccinate	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Quinine	DCHC8C5	Quinine	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + MK-4815	DC5GAUN	MK-4815	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Nitisinone	DCGVY25	Nitisinone	Hepatoblastoma (Cell Line: HB3)	[3]
Sarpogrelate + Atovaquone	DC2B93L	Atovaquone	Hepatoblastoma (Cell Line: HB3)	[3]
Sorafenib + Sarpogrelate	DCOOENN	Sorafenib	DD2 (Cell Line: DD2)	[2]
Sorafenib + Sarpogrelate	DC3ZELQ	Sorafenib	Hepatoblastoma (Cell Line: HB3)	[2]
ZM-447439 + Sarpogrelate	DC8TF3N	ZM-447439	DD2 (Cell Line: DD2)	[2]

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aspirin + Sarpogrelate	DCX5XDB	Aspirin	Coronary Artery Disease	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 210).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [4] ClinicalTrials.gov (NCT02294643) Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study